Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)

Am­gen en­lists TCR start­up TScan to work on Crohn's in deal po­ten­tial­ly worth $500M+

Am­gen is tak­ing a clos­er look at us­ing T cells for in­flam­ma­tion, an­nounc­ing a new deal Tues­day with TCR up­start TScan Ther­a­peu­tics.

The com­pa­nies will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.